ArticleCureus2026
Autosomal Dominant Hypocalcemia With Hypercalciuria Due to a Calcium-Sensing Receptor Gain-of-Function Mutation: A Pediatric Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autosomal dominant hypocalcemia with hypercalciuria (ADHH) is a rare genetic disorder caused by gain-of-function mutations in the calcium-sensing receptor (CaSR) gene. It is characterized by hypocalcemia, inappropriately low parathyroid hormone (PTH), and renal hypercalciuria. We describe a 13-year-old boy who was diagnosed with congenital hypoparathyroidism, persistent hypercalciuria, and mild medullary nephrocalcinosis. Despite calcium and vitamin D supplementation, hypercalciuria was aggravated. Genetic testing revealed a heterozygous c.2518G>A (p.Gly840Ser) mutation in the CaSR gene, classified as likely pathogenic (American College of Medical Genetics and Genomics (ACMG) Class 4). Supplementation was discontinued, and hydrochlorothiazide and potassium citrate were initiated to reduce urinary calcium and alkalinize urine. At the one-year follow-up, renal function remained preserved with no progression of nephrocalcinosis. This case underscores the importance of considering ADHH in children with hypocalcemia, suppressed PTH, and renal hypercalciuria. Early genetic testing prevents misdiagnosis and enables targeted therapy to mitigate long-term renal complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.